ALPHARETTA, Ga.–(BUSINESS WIRE)–Clearside Biomedical, which develops drug therapies for eye diseases, announces completion of Phase 2 clinical trial enrollment for treatment of macular edema associated with non-infectious uveitis.
Category: Business
Aerpio Therapeutics to Present TIME-2 Phase 2a Study of AKB-9778 in Diabetic Macular Edema Data at 2015 American Academy of Ophthalmology Annual Meeting Retina Subspecialty Day
CINCINNATI–(BUSINESS WIRE)–Aerpio Therapeutics, Inc., a biopharmaceutical company focused on advancing first-in-class treatments for the eye, today announced that data from the TIME-2 Phase 2a Study of AKB-9778 in the treatment of patients with diabetic macular edema (DME) will be presented at the upcoming American Academy of Ophthalmology (AAO) Annual Meeting’s Retina Subspecialty Day. In July, the company announced data showing that a combination of AKB-9778 and Lucentis® provided significa
Photometrics® Launches Intelligent Scientific CMOS Camera with Signal Restoration Super Powers
TUCSON, Ariz.–(BUSINESS WIRE)–Photometrics, a manufacturer of high performance scientific cameras for life science applications, today announces the release of its new sCMOS camera, the Photometrics Prime. Prime is the first 4.2 Megapixel scientific CMOS camera available for life science research that actively defeats the negative impact of Poisson noise in low light images. The camera packs a formidable FPGA-based Embedded Signal Processing engine, ESP™, that enables powerful signal restorat
Cegedim Announces the Signature of an Agreement to Acquire Nightingale’s US Business
BOULOGNE-BILLANCOURT, France–(BUSINESS WIRE)–Regulatory News: Cegedim, an innovative technology and services company, today announced the signature of an agreement for the acquisition of the US based Practice Management business of Nightingale Informatix Corporation by its US subsidiary Pulse System, Inc. The acquisition includes the assets of Nightingale’s Medrium, Ridgemark, Secure Connect and Northern Health Products. Jeff Burton, the Pulse Systems President and CEO stated that “We are exc
Presbia Introduces Time-Saving Disposable Microlens Inserter
DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ: LENS), an ophthalmic device company introduced its new, innovative disposable inserter for the Presbia Flexivue Microlens™ at the Australasian Society of Cataract and Refractive Surgeons (AUSCRS) conference held from October 7th through the 10th in Noosa, Queensland, Australia. The Presbia Flexivue Microlens is a proprietary optical lens implant for treating presbyopia, the age-related loss of near-vision. With its simplified action, the new inserte
Cirle Receives Prestigious 2015 Red Dot Design Concept Award for Its 3-D Surgical Navigation System
MIAMI–(BUSINESS WIRE)–Cirle, Inc., a Miami-based medical technology incubator, has won the prestigious “Red Dot Award-Best of the Best” for its 3-D Surgical Navigation System prototype in international design competition.
Resumen: URSAPHARM GmbH y Novaliq GmbH anuncian un acuerdo de colaboración en Europa
SAARBRÜCKEN y HEIDELBERG–(BUSINESS WIRE)–URSAPHARM, una de las empresas líderes en el campo de la oftalmología en Europa, y Novaliq, empresa farmacéutica especializada en estudios clínicos con una plataforma tecnológica para la distribución de fármacos centrada en la oftalmología, han anunciado hoy un acuerdo de colaboración así como el lanzamiento europeo de EvoTears™. El comunicado en el idioma original, es la versión oficial y autorizada del mismo. La traducción es solamente un medio de ay
Increased Technology Use May Lead to Future Eye Health and Vision Issues
MINNEAPOLIS–(BUSINESS WIRE)–Today’s kids use digital devices for hours daily, which may have long term consequences for their eyes and vision. An annual comprehensive eye exam is essential for all children as they enter school.
Optomed Announces New Investment from RBVC
OULU, Finland–(BUSINESS WIRE)–Optomed Oy, Finland based and the world’s fastest growing retinal company received significant investment from Robert Bosch Venture Capital GmbH (RBVC), Germany. “This investment will be used to accelerate growth across the business, to advance our product development and help us to successfully execute our strategy. It is a big recognition towards both our technology and our team in Finland. We are proud to welcome RBVC as one of our investors. With their suppor
Führende Ophthalmologen haben auf dem 15. EURETINA-Kongress praktische klinische Ergebnisse von Oraya Therapy für feuchte AMD präsentiert
NEWARK, Kalifornien (USA) und NIZZA (Frankreich)–(BUSINESS WIRE)–Oraya Therapeutics Inc. gab heute bekannt, dass führende Ophthalmologen aus drei europäischen Ländern auf einem Symposium im Rahmen des 15. Kongresses der europäischen Gesellschaft der Netzhautspezialisten in Nizza an der französischen Riviera die Ergebnisse für die Patienten ein Jahr nach einer einmaligen Behandlung mit der Oraya Therapy für feuchte altersbedingte Makuladegeneration (Age-related Macular Degeneration, AMD) präse
D’éminents ophtalmologues ont présenté les résultats cliniques « du monde réel » sur la thérapie Oraya contre la DMLA exsudative, lors du 15e congrès EURETINA
NEWARK, Californie et NICE, France–(BUSINESS WIRE)–Oraya Therapeutics Inc. a annoncé aujourd’hui que d’éminents ophtalmologues de trois pays européens ont présenté les résultats du suivi de patients un an après un traitement unique par la thérapie Oraya contre la dégénérescence maculaire liée à l’âge (DLMP) exsudative, au cours d’un symposium lors du 15e congrès de la Société européenne des spécialistes de la rétine à Nice, France. Les résultats montrent que la thérapie Oraya est efficace dan
Beyond Baby Shampoo: New Advances in Eyelid Hygiene
NEW YORK–(BUSINESS WIRE)–Omni Eye Services, a leading provider of ophthalmologic services at seven locations in New York and New Jersey, today announced that Dr. Katherine M. Mastrota, Center Director of Omni Eye Surgery in New York City, has written…
Bruker Introduces the rapifleX™ MALDI-TOF/TOF at HUPO
VANCOUVER, British Columbia–(BUSINESS WIRE)–At the 14th Human Proteome Organization World Congress (HUPO), Bruker today announced the new rapifleX MALDI-TOF/TOF mass spectrometer. MALDI-TOF/TOF is established as a powerful tandem mass spectrometry method for in-depth protein analysis. With its redesigned, next-generation TOF/TOF ion optics, the rapifleX system now offers significantly higher speed, mass resolution and mass accuracy. The rapifleX integrates a novel, 10 kHz smartbeam™ 3D scanni
Ocular Therapeutix™ Submits New Drug Application to U.S. Food and Drug Administration for DEXTENZA® for the Treatment of Post-Surgical Ocular Pain
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for DEXTENZA® (sustained release dexamethasone) 0.4mg Intracanalicular Depot, for the treatment of ocular pain following ophthalmic surgery. The data included in the NDA s
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Receives FDA Fast-Track Designation for OpRegen® for the Treatment of the Dry Form of Age-Related Macular Degeneration
ALAMEDA, Calif. & JERUSALEM–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT and TASE: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (“Cell Cure”) today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for OpRegen®, a cell-based therapeutic product consisting of retinal pigment epithelial (RPE) cells designed to block the progression of the severe dry-form of age-related macular degeneration (AMD), a leading cause of blindness in an aging populatio
Aerie Pharmaceuticals Initiates Fourth Phase 3 Clinical Trial of RhopressaTM
IRVINE , Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that on September 23, dosing commenced of the first patients enrolled in Rocket 4, the Company’s fourth Phase 3 clinical trial of RhopressaTM, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with
Research and Markets: Dry Eye Syndrome Forecast in 7 Major Markets 2015-2025 – USA, France, Germany, Italy, Spain, UK and Japan
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/bt4gdd/epiomic) has announced the addition of the “Epiomic Epidemiology Series: Dry Eye Syndrome Forecast in 7 Major Markets 2015-2025” report to their offering. …
Tyrogenex Presents Final Results from Phase 1 Study of X-82 for Wet AMD at the 15th EURETINA Congress
NEEDHAM, Mass., & PALM BEACH GARDENS, Fla.–(BUSINESS WIRE)–Tyrogenex, focused on next-gen targeted therapeutics for ophthalmology, presented data from its phase 1 safety study of orally-administered X-82 in patients for wet AMD at EURETINA Congress.
Presbia Flexivue Microlens™ Implanted in More Than 1,000 Patients Worldwide
DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ: LENS), an ophthalmic medical device company and leader in near-vision restoration announced today that more than 1000 patients worldwide have been treated with the Presbia Flexivue Microlens™. “We are very pleased to announce this significant milestone,” said Todd Cooper, President and CEO of Presbia. “As we expand the commercialization of our Microlens into additional countries around the world, we are thrilled by the feedback we are receiving from
Aerie Pharmaceuticals Reports Positive Rhopressa™ Phase 3 Efficacy Results
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported the successful results of its second Phase 3 trial for Rhopressa™, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The trial achieved its primary efficacy endpo